Combination of | |
---|---|
Olopatadine | Selective histamine H1-receptor antagonist |
Mometasone | Corticosteroid |
Clinical data | |
Trade names | Ryaltris |
Other names | GSP 301 |
License data | |
Pregnancy category |
|
Routes of administration | Nasal spray |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. [1] [2] [3] It contains olopatadine hydrochloride and mometasone furoate monohydrate. [1] [2] It is sprayed into the nose. [1] [2]
Common side effects include an unpleasant taste ( dysgeusia). [1]
It was approved for medical use in Australia in December 2019, [1] [4] and in the United States in January 2022. [2]